StockData
Evommune, Inc. logo

Evommune, Inc. (EVMN) stock

EVMNNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$7.02−0.08 (-1.13%)

Close on Nov 17, 2026Market cap $254.77MP/E –Yield –

Evommune profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Evommune's profit margin for the twelve months ending Jun 30, 2026 was -946.7%. For fiscal 2025 it was -529.8%, against -954.4% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-529.8%+424.6
FY2024Dec 31, 2024-954.4%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2025Sep 30, 2025-124.8%–
Q1 FY2025Mar 31, 2025-485.2%–

More Evommune figures

See a number that looks wrong?